#United States #Aetna #Bryan #Vitiligo #Phothera

Aetna Expands Coverage for Vitiligo Treatment

In a significant development in the field of dermatology, Aetna has updated its coverage policy, now including home phototherapy for individuals suffering from vitiligo. This change, effective July 2026, represents a crucial advancement for millions affected by the skin condition.

Why This Change Matters

Vitiligo is a chronic skin disorder affecting approximately 1% of the American population, translating to around 2 to 3 million individuals. Many patients often encounter obstacles when attempting to access phototherapy treatments, either being denied coverage or facing exorbitant out-of-pocket expenses. The newly revised Aetna policy provides these individuals with a clearer path towards necessary phototherapy, particularly the increasingly predominant method known as narrow-band ultraviolet B (NB-UVB) phototherapy, which can now be administered at home.

Padma Sundar, the Chief Commercial Officer at Phothera, emphasized the significance of this change, stating, "This is exactly the kind of progress our patients deserve. Vitiligo is a chronic, often deeply personal condition, and phototherapy has long been underutilized simply because access barriers stood in the way. Coverage that includes home phototherapy matters because convenience drives consistency."

Recent clinical trials revealed that patients utilizing home-based phototherapy showed adherence rates nearly three times higher compared to those relying solely on in-office treatments. This substantial difference highlights the effectiveness of at-home treatments, which enhance the patient’s ability to stick to their prescribed therapy.

A Part of a Larger Trend

Aetna's progressive step is part of a broader trend in the healthcare industry, reflecting a shift towards better insurance coverage for phototherapy treatments. Following similar advancements by other insurers like Anthem/BCBS and Cigna, the expansion suggests growing recognition of the importance of accessible treatment options for chronic skin conditions. Numerous patients suffering from chronic skin diseases, including psoriasis and eczema, can now benefit from enhanced coverage that extends to home phototherapy.

"Our internal analysis indicates that a majority of insured patients now have access to home phototherapy coverage across various skin conditions," explained Sundar.

Streamlined Prescribing Process

Not only has coverage become more inclusive, but the process for prescribing home phototherapy has also been simplified through Phothera’s integration with electronic medical record systems such as EMA and Epic. This integration allows dermatologists to prescribe home treatments directly from their existing medical records system, eliminating the need for separate portals and redundant data entry, thus facilitating a smoother clinical workflow.

About Phothera

Phothera is at the forefront of manufacturing FDA-approved phototherapy devices aimed at treating chronic skin conditions. The company formed from the merger of Daavlin and National Biological Corporation, operating under Madison Industries. Phothera combines over 80 years of experience in phototherapy technologies, committed to advancing patient care and treatment outcomes for conditions like vitiligo, psoriasis, atopic dermatitis, and cutaneous T-cell lymphoma.

With this newly revised Aetna policy, patients can look forward to more accessible and effective treatment alternatives for vitiligo, promoting better health outcomes and enhancing their quality of life. Moving forward, the medical community anticipates that these changes will encourage further innovations and improvements in dermatological care.

• ---

In summary, Aetna's decision marks a milestone for those living with vitiligo, unshackling patients from previous limitations and offering them a clearer, more manageable path toward effective treatment. With the help of organizations like Phothera, dermatology continues to advance towards a more inclusive and patient-friendly future.